Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

Blood

Volumn 98, Issue 3, 2001, Pages 805-813

  Grad, Jennifer M ^a,b   Bahlis, Nizar J ^a,b   Reis, Isildinha ^a,b   Oshiro, Marc M ^a,b   Dalton, William S ^a,b   Boise, Lawrence H ^a,b,c  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASCORBIC ACID; FREE RADICAL; GLUTATHIONE; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CONJUGATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REMISSION; VITAMIN METABOLISM;

EID: 0035437189     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.3.805     Document Type: Article

References (66)

1. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3-21.
2. Anderson KC, Kyle RA, Berenson JR, Dalton WS. Recent advances in the biology and treatment of multiple myeloma. Washington, DC: American Society of Hematology Education Program; 1998:63-88.
3. Kishi Y, Oki Y, Machida U. Thalidomide in multiple myeloma. N Engl J Med. 2000;342:975-976.
4. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 1996;32A:912-920.
5. Fisher GA, Lum BL, Hausdorff J, Sikic BI. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer. 1996;32A:1082-1088.
6. Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood. 1992;79:213-222.
7. Gomi M, Moriwaki K, Katagiri S, Kurata Y, Thompson EB. Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA. Cancer Res. 1990;50:1873-1878.
8. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989;7:415-424.
9. Epstein J, Xiao HQ, Oba BK. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood. 1989;74:913-917.
10. Dalton WS, Durie BG, Alberts DS, Gerlach JH, Cress AE. Characterization of a new drug resistant multiple myeloma cell line that expresses P-glycoprotein. Cancer Res. 1986;46:5125-5130.
11. Salmon SE, Dalton WS, Grogan TM, et al. Multidrug resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood. 1991;78:44-50.
12. Sonneveld P, Lokhorst HM, Vossebeld P. Drug resistance in multiple myeloma. Semin Hematol. 1997;34(suppl 5):34-39.
13. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941-2953.
14. Tu Y, Renner S, Xu F, et al. Bcl-XL expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 1998;58:256-262.
15. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83-85.
16. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-872.
17. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan resistant human multiple myeloma cell line. Cancer Res. 1991;51:995-1002.
18. Gupta V, Singh SV, Ahmad H, Medh RD, Awasthi YC. Glutathione and glutathione S-transferases in a human plasma cell line selected for resistance to melphalan. Biochem Pharmacol. 1989;38:1993-2000.
19. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348.
20. Zhang W, Ohnishi K, Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia. 1998;12:1383-1391.
21. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett. 1999;455(1-2):59-62.
22. Akao Y, Mizoguchi H, Kojima S, Naoe T, Ohishi N, Yagi K. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Hematol. 1998;102:1055-1060.
23. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer. 1999;81:796-799.
24. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000;95:1014-1022.
25. 3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052-1061.
26. Lo JF, Wang HF, Tam MF, Lee TC. Protein glutathione S-transferase π in an arsenic-resistant Chinese hamster ovary cell line. Biochem J. 1992;288(pt 3):977-982.
27. Lee TC, Wei ML, Chang WJ, et al. Elevation of glutathione levels and glutathione S-transferase activity in arsenic-resistant Chinese hamster ovary cells. In Vitro Cell Dev Biol. 1989;25:442-448.
28. Kala SV, Neely MW, Kala G, et al. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem. 2000;275:33404-33408.
29. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999;93:268-277.
30. Scott N, Hatlelid KM, MacKenzie NE, Carter DE. Reactions of arsenic(III) and arsenic(V) species with glutathione. Chem Res Toxicol. 1993;6:102-106.
31. O'Dwyer PJ, LaCreta F, Nash S, et al. Phase I study of thio-TEPA in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res. 1991;51:6059-6065.
32. Lacreta FP, Brennan JM, Nash SL, Comis RL, Tew KD, O'Dwyer PJ. Pharmacokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther. 1994;270:1186-1191.
33. Petrini M, Conte A, Caracciolo F, Sabbatini A, Grassi B, Ronca G. Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient. Br J Haematol. 1993;85:409-410.
34. Prezioso JA, Fitzgerald GB, Wick MM. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. J Invest Dermatol. 1992;99:289-293.
35. Bailey HH, Ripple G, Tutsch KD, et al. Phase I study of continuous-infusion L-S, R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 1997;89:1789-1796.
36. Block G, Levine M. Vitamin C: a new look. Ann Intern Med. 1991;114:909-910.
37. Sakagami H, Satoh K. Modulating factors of radical intensity and cytotoxic activity of ascorbate [review]. Anticancer Res. 1997;17:3513-3520.
38. Bijur GN, Ariza ME, Hitchcock CL, Williams MV. Antimutagenic and promutagenic activity of ascorbic acid during oxidative stress. Environ Mol Mutagen. 1997;30:339-345.
39. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat-3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115.
40. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997;90:2863-2892.
41. Zhu XH, Shen YL, Jing YK, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 1999;91:772-778.
42. Hardin J, Leod S, Grigorieva I, et al. IL-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84:3063-3070.
43. Xu F, Sharma S, Gardner A, et al. IL-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood. 1998;92;241-251.
44. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. IL-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995:162;248-255.
45. Gauthier ER, Piche L, Lemieux G, Lemieux R. Role of Bcl-xL in the control of apoptosis in murine myeloma cells. Cancer Res. 1996;56:1451-1456.
46. 3) in high-risk refractory multiple myeloma [abstract]. Blood. 1999;94(pt 1):123.
47. Vera JC, Rivas CI, Fischbarg J, Golde DW. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature. 1993;364:79-82.
48. Welch RW, Wang Y, Crossman A Jr, Park JB, Kirk KL, Levine M. Accumulation of vitamin C (ascorbate) and its oxidized metabolite dehydroascorbic acid occurs by separate mechanisms. J Biol Chem. 1995;270:12584-12592.
49. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. JAMA. 1999;281:1415-1423.
50. Broeks A, Gerrard B, Allikmets R, Dean M, Plasterk RH. Homologues of the human multidrug resistance genes MRP and MDR contribute to heavy metal resistance in the soil nematode Caenorhabditis elegans. EMBO J. 1996;15:6132-6143.
51. r 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 1994;54:5788-5792.
52. Abbaszadegan MR, Foley NE, Gleason-Guzman MC, Dalton WS. Resistance to the chemosensitizer verapamil in a multidrug resistant (MDR) human multiple myeloma cell line. Int J Cancer. 1996;66:506-514.
53. Hipfner DR, Akmquist KC, Stride BD, Deeley RG, Cole SPC. Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. Cancer Res. 1996;56:3307-3314.
54. Loe DL, Stewart RK, Massey TE, Deeley RG, Cole SPC. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol. 1997;51:1034-1041.
55. Flens MJ, Izquierdo MA, Scheffer GL, et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994;54:4557-4563.
56. Watson RW, Redmond HP, Wang JH, BouchierHayes D. Mechanism involved in sodium arsenite-induced apoptosis of human neutrophils. J Leukoc Biol. 1996;60:625-632.
57. Lee TC, Ko JL, Jan KY. Differential cytotoxicity of sodium arsenite in human fibroblasts and Chinese hamster ovary cells. Toxicology. 1989;56:289-299.
58. Ochi T, Kaise T, Oya-Ohta Y. Glutathione plays different roles in the induction of the cytotoxic effects of inorganic and organic arsenic compounds in cultured BALB/c 3T3 cells. Experientia. 1994;50:115-120.
59. Ochi T, Nakajima F, Sakurai T, Kaise T, Oya-Ohta Y. Dimethylarsinic acid causes apoptosis in HL-60 cells via interaction with glutathione. Arch Toxicol. 1996;70:815-821.
60. Nooter K, Burger H, Stoter G. Multidrug resistance-associated protein (MRP) in haematological malignancies. Leuk Lymphoma. 1996;20:381-387.
61. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res. 1994;54:4676-4679.
62. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227-234.
63. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol. 1997;97:429-440.
64. Damiano JS, Cress AE, Hazelhurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-1667.
65. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360.
66. Ludwig S, Hoffmeyer A, Goebeler M, et al. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J Biol Chem. 1998;273:1917-1922